Search

Skip to main content Accessibility help

Home
Search

Only show content I have access to (0)

Chapters (1)

Over 3 years (1)

From year:

To year:

Apply

Medicine (1)

transient rash

Cambridge University Press (1)

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to .

To save content items to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

1 results

47 - Combination therapy in multiple sclerosis
from Section III - Clinical trials of multiple sclerosis therapies
- By Michelle Fabian, Fred D. Lublin
Edited by Jeffrey A. Cohen, Richard A. Rudick
Book:

Multiple Sclerosis Therapeutics

Published online:

05 December 2011

Print publication:

20 October 2011, pp 547-556
- Chapter
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation
Summary

Repeated administration of intravenous immunoglobulin (IVIG) to improve the course of multiple sclerosis (MS) has now been tested in almost all stages of the disease, although to a variable extent and with various study designs. To date, two clinical trials have tested the effects of IVIG on progressive forms of MS. The efficacy of IVIG has been explored in several stages and settings of MS ranging from attempts to ameliorate the acute attack via investigations on the effects of long term immunomodulation to attempts of restoration of fixed deficits. Due to the good tolerability of IVIG, it has been recommended as a possible means to lessen disease activity that may be seen after delivery in some MS patients. The side effects observed at lower dosages of IVIG have been uniformly minor and consisted primarily of headaches, malaise, or a transient rash.